WEBULL
News
HBIO
0.6010
+13.37%
0.0709
Harvard Bioscience outlines strategy for growth
TipRanks · 16h ago
Harvard Bioscience Reports Q4 Preliminary Revenue Of $23.7M
Benzinga · 16h ago
HARVARD BIOSCIENCE INC - EXPECTS YEAR OVER YEAR REVENUE GROWTH AND MID-TO HIGH-SINGLE-DIGIT EBITDA GROWTH IN 2026
Reuters · 16h ago
*Harvard Bioscience Sees 4Q Rev $22.5M-$24.5M >HBIO
Dow Jones · 16h ago
Press Release: Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas
Dow Jones · 16h ago
Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas
Barchart · 22h ago
Weekly Report: what happened at HBIO last week (0202-0206)?
Weekly Report · 1d ago
Weekly Report: what happened at HBIO last week (0126-0130)?
Weekly Report · 02/02 10:17
Harvard Bioscience files to sell 9.5M shares of common stock for holders
TipRanks · 01/30 22:05
Harvard Bioscience Trims Footprint To Run Leaner, Faster, And Cheaper
Benzinga · 01/30 11:49
Harvard Bioscience Announces Major Global Manufacturing Consolidation
TipRanks · 01/29 22:24
Harvard Biosciene to Close Massachusetts Manufacturing Plant
Dow Jones · 01/29 22:19
*Harvard Bioscience: Initiative Expected to Deliver Approximately $3M in Cost Savings in 2027 and $4M in Annual Cost Savings Beginning in 2028 While Improving Throughput and Execution >HBIO
Dow Jones · 01/29 21:51
*Harvard Bioscience: Will Close Manufacturing Facility in Holliston and Transition U.S. Production to Manufacturing Hub in Minneapolis >HBIO
Dow Jones · 01/29 21:51
*Harvard Bioscience: Streamlining Production Footprint and Improving Manufacturing Efficiency Through Phased Closure of Holliston, Mass., Plant >HBIO
Dow Jones · 01/29 21:51
Harvard Bioscience closes manufacturing operations in Massachusetts
TipRanks · 01/29 21:50
HARVARD BIOSCIENCE INC: CERTAIN OPERATIONS WILL ALSO BE RELOCATED TO FACILITIES IN GERMANY, SWEDEN, AND UK
Reuters · 01/29 21:39
Harvard Bioscience Shifts Manufacturing to Minneapolis and Europe
Reuters · 01/29 21:31
HARVARD BIOSCIENCE INC - EXPECTS $3 MLN SAVINGS IN 2027, $4 MLN ANNUALLY FROM 2028
Reuters · 01/29 21:30
HARVARD BIOSCIENCE: SAVINGS INCLUDE REDUCED OVERHEAD, IMPROVED ASSET UTILIZATION, TARGETED RECONFIGURATION OF WORKFORCE ACROSS IMPACTED OPS
Reuters · 01/29 21:30
More
Webull provides a variety of real-time HBIO stock news. You can receive the latest news about Harvard Biosci through multiple platforms. This information may help you make smarter investment decisions.
About HBIO
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.